Literature DB >> 18186543

Synthesis and cytotoxic activity of imidazo[1,2-a]-1,3,5-triazine analogues of 6-mercaptopurine.

Franciszek Saczewski1, Magdalena Maruszak, Patrick J Bednarski.   

Abstract

A series of 2-substituted imidazo[1,2-a]-1,3,5-triazines with various aliphatic and aromatic amines has been prepared and characterized by IR,1H-NMR, and elemental analysis. The initial in-vitro cytotoxicity studies with five human cancer cell lines showed that all but one of the compounds are without cytotoxic activity. The one active compound, 2-(indolin-1-yl)-7,8-dihydroimidazo[1,2-a]-1,3,5-triazine-4(6H)-thione 12, was tested on 12 human cancer cell lines. Of these, two lines, RT-4 and MCF-7, were the most sensitive to the compound, with IC50 values of 6.98 microM and 8.43 microM, respectively. When compared with the reference anticancer drug 6-mercaptopurine, only the RT-4 urinary bladder and KYSE-70 oesophagus cancer cell lines were more sensitive to the new compound. The antimetabolite thioguanine was more cytotoxic than 12 for all common cell lines tested.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18186543     DOI: 10.1002/ardp.200700176

Source DB:  PubMed          Journal:  Arch Pharm (Weinheim)        ISSN: 0365-6233            Impact factor:   3.751


  3 in total

1.  Small Molecule Ligands For Active Targeting Of TrkC-expressing Tumor Cells.

Authors:  Eunhwa Ko; Anyanee Kamkaew; Kevin Burgess
Journal:  ACS Med Chem Lett       Date:  2012-10-09       Impact factor: 4.345

2.  One-pot synthesis of 1,3,5-triazine-2,4-dithione derivatives via three-component reactions.

Authors:  Gui-Feng Kang; Gang Zhang
Journal:  Beilstein J Org Chem       Date:  2020-06-24       Impact factor: 2.883

3.  A one-pot, multicomponent reaction for the synthesis of novel 2-alkyl substituted 4-aminoimidazo[1,2-a][1,3,5]triazines.

Authors:  Felicia Phei Lin Lim; Lin Yuing Tan; Edward R T Tiekink; Anton V Dolzhenko
Journal:  RSC Adv       Date:  2018-06-12       Impact factor: 3.361

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.